全球银屑病治疗药物市场研究报告 Psoriasis Drugs - A Global Strategic Business Report

Transcription

1 全球银屑病治疗药物市场研究报告 Psoriasis Drugs - A Global Strategic Business Report : / :568 : :3950 / + : : : Psoriasis Drugs This report analyzes the worldwide markets for Psoriasis Drugs in US$ Million by the following Drug Administration Routes - Systemic Drugs, and Topical Drugs. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through The report profiles 69 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Almirall SA, Astellas Pharma US, Inc., Biogen Idec, Inc., Eisai Co. Ltd., Galderma Laboratories, Isis Pharmaceuticals, Inc., Johnson & Johnson Company, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Stiefel Laboratories, Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Vertex Pharmaceuticals, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report. Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study Systemic Drugs Topical Drugs II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Psoriasis - A Chronic, Widespread Autoimmune Disease

2 Table 1: World Psoriasis Prevalence (in Million) in Select Countries: (includes Psoriasis Poses Risk for Cardiovascular Diseases Quick Facts About Psoriasis Disease Quick Facts About Psoriasis Treatment Global Market Outlook Psoriasis Drugs Overview Major Marketed Drugs for Psoriasis Treatment as of 2009 Topical Drugs Overview Table 2: World Psoriasis Drugs Market - Value Sales of Select Leading Topical Products in US$ Million for 2008 (includes Foams and Liquid Formulations Gaining Momentum JAK3 Inhibitors Spell Promising Future for Topical Drugs Systemic Drugs Overview Table 3: World Psoriasis Drugs Market - Value Sales of Select Leading Conventional Systemic Products in US$ Million for 2007 (includes corresponding Graph/Chart) Enbrel - The Market Leader 2. KEY MARKET TRENDS Market Welcomes New Products, Even As Established Biologic Makes Exit Conventional Topical Therapies to Remain Mainstay Treatment Biologics to Witness Robust Growth, Driven by New Product Introductions Interleukin and TNF-Alpha Inhibitors to Drive Biologics Growth TNF-Alpha Blockers - The Market Leaders Table 4: World Psoriasis Drugs Market - Value Sales of Select Leading Biologic Systemic Products in US$ Million for 2008(includes Interleukin Inhibitors - The Next Big Biologic Class Non-Prescriptions and Generics Threaten Market Growth Oral Pipeline Therapies To Take On Biologics Home Ultraviolet B Therapy to Find Favor with Psoriasis Patients Paradigm of Psoriasis Treatment Voclosporin to Edge Out Competitive Products Apremilast to OUTdo Existing Anti-TNF Products 3. PIPELINE ANALYSIS The Research Progress in Psoriasis Treatment Safety Plays Critical Role in Psoriasis Therapy Major Drug Candidates in Pipeline Existing and Future Research & Development Approach Table 5: Psoriasis Drugs Pipeline (2009) - Number of Pipeline Candidates and Clinical Trials (includes Select Psoriasis Pipeline Candidates for Topical Treatment as of 2009 Select Psoriasis Pipeline Candidates for Oral Treatment as of 2009 Select Psoriasis Pipeline Candidates for Injectable Treatment as of 2009

3 Other Major Psoriasis Pipeline Candidates in Phase II Clinical Trials as of 2009 NIAID Researchers Identify Potential New Drug Target 4. ALL ABOUT PSORIASIS What is Psoriasis? The History of Psoriasis The History of Psoriasis Treatment The Risk Factors of Psoriasis The Cause(s) of Psoriasis The Aggravating Factors The Diagnosis of Psoriasis The Severity of Psoriasis The Types of Psoriasis Plaque Psoriasis Scalp Psoriasis Nail Psoriasis Inverse Psoriasis Guttate Psoriasis Pustular Psoriasis Erythrodermic Psoriasis Psoriatic Arthritis Others The Treatment of Psoriasis The Three-Step Approach to Treatment Treatment by Disease Severity Mild Stage Psoriasis Treatment Moderate Stage Psoriasis Treatment Severe Stage Psoriasis Treatment Treatment by Natural Healing Other Treatment 5. OVERVIEW OF PSORIASIS TREATMENT Table 6: Therapeutic Modalities for Psoriasis Treatment in Percentage by Disease Stage (includes Topical Treatment List of Topical Therapies Available for the Treatment of Mild-to-Moderate Psoriasis Select Topical Drugs Clobex (Clobetasol propionate) Dovonex (calcipotriene) Olux-E (Clobetasol propionate) Taclonex/ Dovobet/ Daivobet (calcipotriene/ betamethasone) Tazorac (Tazarotene) Vectical (calcitriol) Systemic Treatment

4 Select Conventional Systemic Drugs Methotrexate Soriatane (acitretin) Neoral (cyclosporine) Tegison (etrentinate) NSAIDs Biologic Systemic Therapies List of Approved Biologic Systemic Therapies for Psoriasis Select Biologic Drugs Amevive (alefacept) Enbrel (etanercept) Humira (adalimumab) Remicade (infliximab) Raptiva (efalizumab) Stelara (ustekinumab) Phototherapy UVB Phototherapy PUVA Phototherapy Alternative Treatment Climatotherapy 6. SELECT CLINICAL TRIALS Isotechnika s Voclosporin Shows Favorable Results in Phase III Clinical Trial Provectus Commences New Clinical Trials for Psoriasis Micromet Initiates First Clinical Study for GM-CSF Human Antibody MT203 Welichem Initiates GLP Toxicology Studies for Anacor Announces Favorable Phase II Trial Results of AN2728 Synvista Initiates Phase II Clinical Trial of Topical Avontec Announces Positive Results from Phase IIa Clinical Trial of UE Revotar Announces Favorable Phase I Trial Results of Bimosiamose 5% Cream Manhattan Completes Enrollment in Phase IIa Clinical Trial of Topical PTH (1-34) Dermipsor Announces Positive Results from Phase IIb Clinical Trial of BioCryst Completes Phase IIa Study, Announces Promising Results of Arana Therapeutics Completes Patient Recruitment in Phase II Trial of ART621 Novartis Exploratory Development Study Shows Positive Results for AEB PRODUCT LAUNCHES/ APPROVALS Eisai Obtains Japanese Approval for HUMIRA in Psoriasis Treatment Janssen-Cilag Launches Stelara for Plaque Psoriasis PsoriasisDX Launches Genetic Test for Psoriatic Arthritis Elorac Launches Zithranol-RR for Plaque Psoriasis Quinnova Introduces New Treatment for Hyperkeratotic Conditions Xderma Launches New Ointment for Psoriasis Promius Pharma Introduces Scytera Foam 2% for Chronic Psoriasis NeoStrata Launches PSORENT

5 LEO Pharma to Launch Xamiol Glenmark Introduces Dermatology Products The Kuwait Health Ministry Approves Alalorid for Psoriasis Treatment CHMP s Positive Recommendation for Enbrel as Psoriasis Treatment in Children 8. RECENT INDUSTRY ACTIVITY Cephalon Acquires Arana Therapeutics GlaxoSmithKline to Acquire Stiefel Laboratories PhotoMedex Acquires Photo Therapeutics PPD Acquires Magen BioSciences Bristol-Myers Squibb Acquires Medarex Valeant Pharmaceuticals Acquires Dow Pharmaceutical Sciences Advitech to Acquire Botaneco Specialty Ingredients Merck Merges with Schering-Plough Pfzer Acquires Wyeth Paladin Labs and Isotechnika Pharma Enter into Partnership Centocor Ortho Biotech Obtains FDA Approval for Golimumab Centocor Ortho Biotech Obtains FDA Approval for Stelara Galderma Receives Approval from FDA for Vectical LEO Pharma Reacquires Product Licensing Rights from Warner Chilcott Genentech Withdraws Raptiva from US Market Prime Pharmaceutical Grants License of Relieva to Mac Pharma Dynavax Receives Grant to Support TLR Inhibitors Development from NIAID Valeant Pharmaceuticals Takes Over DermaTech Bayer Takes Over Direvo Biotech Stiefel Laboratories Acquires Barrier Therapeutics Biotie Therapies Enters in Agreement to Acquire elbion Galderma Acquires Collagenex Abbott Obtains FDA Approval for HUMIRA in Psoriasis Treatment LEO Pharma and Warner Chilcott Obtain FDA Approval for Taclonex Scalp Cytos Joins Hands with Pfizer to Develop Vaccines Karo Bio and Zylus Cadila Enter into Collaboration Dermipsor Collaborates with Department of Veterans Affairs and VA Boston Research Institute GlaxoSmithKline Signs Deal with Dynavax Technologies RXi Pharmaceuticals Receives Technology License from UMMS Heilongjiang Tianlong Receives Manufacturing Rights for Four Medicines Dara BioSciences Raises Funds for Testing of Drugs Avidas Pharmaceuticals Acquires Rights from Crown Laboratories LEO Pharma Sets Up LEO Pharma China Dr Reddy's Established New Subsidiary in the US Lupin to Outlicense Psoriasis Drugs 9. FOCUS ON SELECT PLAYERS Abbott Laboratories (US) Amgen Inc. (US) Almirall SA (Spain) Astellas Pharma US, Inc. (US) Biogen Idec, Inc. (US) Eisai Co. Ltd. (Japan)

6 Galderma Laboratories (Switzerland) Isis Pharmaceuticals, Inc. (US) Johnson & Johnson Company (US) LEO Pharma A/S (Denmark) Merck & Co., Inc. (US) Novartis AG (Switzerland) Stiefel Laboratories, Inc. (US) Teva Pharmaceutical Industries Ltd. (Israel) Valeant Pharmaceuticals International (US) Vertex Pharmaceuticals, Inc. (US) Wyeth (US) 10. GLOBAL MARKET PERSPECTIVE Analytics by Geographic Region Table 7: World Recent Past, Current & Future Analysis for Psoriasis Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes Table 8: World 10-Year Perspective for Psoriasis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 and 2015 (includes Analytics by Drug Administration Route Table 9: World Recent Past, Current & Future Analysis for Psoriasis Drugs by Drug Administration Route - Systemic Drugs and Topical Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes Table 10: World 10-Year Perspective for Psoriasis Drugs by Drug Administration Route - Percentage Breakdown of Dollar Sales for Systemic Drugs and Topical Drugs Markets for Years 2006, 2009 and 2015 III. MARKET 1. UNITED STATES A. Market Analysis Current and Future Analysis Major Trends Corticosteroids: Foundation of Mild to Moderate Treatment Dovonex, Taclonex Remain Standard Topical Treatments Room for Biologics Penetration As Most Moderate-to- Severe Cases Remain Untreated for Psoriasis Enbrel to Lead, Despite Losing Share to Humira Humira Cuts into Enbrel s Share Amgen to Redeem 100% North American Rights for Enbrel J&J's Stelara Unlikely to Take the Market By Storm FDA Delays Enbrel s Pediatric Psoriasis Indication Genentech Withdraws Raptiva, Triggers Safety Concerns Product Launches Strategic Corporate Developments

7 Key Players B. Market Analytics Table 11: US Recent Past, Current & Future Analysis for Psoriasis Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) 2. JAPAN A. Market Analysis Current and Future Analysis Key Player B. Market Analytics Table 12: Japanese Recent Past, Current & Future Analysis for Psoriasis Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes 3. EUROPE A. Market Analysis Current and Future Analysis Product Launches Strategic Corporate Developments Key Players B. Market Analytics Table 13: European Recent Past, Current & Future Analysis for Psoriasis Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes 4. REST OF WORLD A. Market Analysis Current and Future Analysis Product Launches Strategic Corporate Developments B. Market Analytics Table 14: Rest of World Recent Past, Current & Future Analysis for Psoriasis Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 69 (including Divisions/Subsidiaries - 75) Region/Country Players The United States 46 Canada 3 Japan 1 Europe 14 Germany 2